dc.contributor.author | Beykou, M | |
dc.contributor.author | Arias-Garcia, M | |
dc.contributor.author | Roumeliotis, TI | |
dc.contributor.author | Choudhary, JS | |
dc.contributor.author | Moser, N | |
dc.contributor.author | Georgiou, P | |
dc.contributor.author | Bakal, C | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-15T14:27:11Z | |
dc.date.available | 2022-09-15T14:27:11Z | |
dc.date.issued | 2022-07-11 | |
dc.identifier | ARTN 395 | |
dc.identifier | 10.1038/s41597-022-01512-1 | |
dc.identifier.citation | Scientific Data, 2022, 9 (1), pp. 395 - | |
dc.identifier.issn | 2052-4463 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5489 | |
dc.identifier.eissn | 2052-4463 | |
dc.identifier.eissn | 2052-4463 | |
dc.identifier.doi | 10.1038/s41597-022-01512-1 | |
dc.description.abstract | When used in combination with hormone treatment, Palbociclib prolongs progression-free survival of patients with hormone receptor positive breast cancer. Mechanistically, Palbociclib inhibits CDK4/6 activity but the basis for differing sensitivity of cancer to Palbociclib is poorly understood. A common observation in a subset of Triple Negative Breast Cancers (TNBCs) is that prolonged CDK4/6 inhibition can engage a senescence-like state where cells exit the cell cycle, whilst, remaining metabolically active. To better understand the senescence-like cell state which arises after Palbociclib treatment we used mass spectrometry to quantify the proteome, phosphoproteome, and secretome of Palbociclib-treated MDA-MB-231 TNBC cells. We observed altered levels of cell cycle regulators, immune response, and key senescence markers upon Palbociclib treatment. These datasets provide a starting point for the derivation of biomarkers which could inform the future use CDK4/6 inhibitors in TNBC subtypes and guide the development of potential combination therapies. | |
dc.format | Electronic | |
dc.format.extent | 395 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PORTFOLIO | |
dc.relation.ispartof | Scientific Data | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Cyclin-Dependent Kinase 4 | |
dc.subject | Cyclin-Dependent Kinase 6 | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Proteome | |
dc.subject | Proteomics | |
dc.subject | Triple Negative Breast Neoplasms | |
dc.title | Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-06-28 | |
dc.date.updated | 2022-09-15T14:26:50Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41597-022-01512-1 | |
rioxxterms.licenseref.startdate | 2022-07-11 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35817775 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Dynamical Cell Systems | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1038/s41597-022-01512-1 | |
pubs.volume | 9 | |
icr.researchteam | Prote & Metabolomics Fac | |
icr.researchteam | Dynamical Cell Systems | |
dc.contributor.icrauthor | Roumeliotis, Theodoros | |
dc.contributor.icrauthor | Choudhary, Jyoti | |
dc.contributor.icrauthor | Bakal, Christopher | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-15. Deposit type is initial. No. of files: 1. Files: Proteomic characterisation of triple negative breast cancer cells following CDK46 inhibition.pdf | |